Compare CAPL & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPL | RGNX |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.1M | 793.5M |
| IPO Year | 2012 | 2015 |
| Metric | CAPL | RGNX |
|---|---|---|
| Price | $21.45 | $7.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $23.58 |
| AVG Volume (30 Days) | 24.4K | ★ 1.4M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.74% | N/A |
| EPS Growth | ★ 96.15 | 18.08 |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,869,806,000.00 | $10,393,000.00 |
| Revenue This Year | $20.96 | N/A |
| Revenue Next Year | $15.62 | $22.42 |
| P/E Ratio | $27.64 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $19.78 | $5.46 |
| 52 Week High | $24.63 | $16.19 |
| Indicator | CAPL | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 38.53 |
| Support Level | $21.28 | $5.67 |
| Resistance Level | $21.75 | $7.32 |
| Average True Range (ATR) | 0.39 | 0.45 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 26.67 | 12.92 |
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments, namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.